Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-167-6 | CAS number: 557-28-8
Endpoint summary
Administrative data
Description of key information
No acute toxicity study with zinc dipropionate is available, thus the acute toxicity will be addressed with existing data on its two individual moieties zinc and propionate, respectively propionic acid.
Based on in vivo acute toxicity data on the moieties, it can safely be assumed, that zinc dipropionate has no pronounced acute toxicity.
Please refer to the section for the respective assessment entity for data on the moieties.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
An acute toxicity leading to clasification is not expected for zinc dipropionate, since the two moieties zinc and propionate, respectively propionic acid are not classified for acute toxicity. Under the assumption that the moieties of zinc dipropionate show their toxicological profile individually upon dissolution, acute toxicity estimates (ATE) for the acute oral and inhalative (systemic) toxicity of zinc dipropionate can be calculated using the equation given in regulation (EC) 1272/2008, Annex I, Section 3.1.3.6.1.
Because of lacking of a dose descriptor for the acute dermal toxicity of the zinc moiety, an acute toxicity estimates (ATE) for the acute dermal (systemic) toxicity of zinc dipropionate can not be calculated. However, the dose descriptors for the acute toxicity of the moieties via the oral route are very high (substantially > 2000 mg/kg bw). Thus, it can safely be assumed, that zinc dipropionate has no pronounced acute dermal toxicity.
There are no indications on narcotic effects.
For further information on the toxicity of the individual moieties, please refer to the relevant sections in the IUCLID and CSR.
Justification for classification or non-classification
Based on in vivo acute toxicity data on the moieties, it can safely be assumed, that zinc dipropionate has no pronounced acute toxicity. There are no indications on narcotic effects.
According to the criteria of REGULATION (EC) No 1272/2008 and its subsequent adaptions, Zinc dipropionate does neither have to be classified and has neither obligatory labelling requirement for acute oral, inhalative or dermal toxicity nor for specific target organ toxicity after single exposure (STOT SE narcotic effects).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
